Participation of central and peripheral κ1 and κ2 opioid receptors in arrhythmogenesis

Yury B. Lishmanov, Leonid N. Maslov, Dina S. Ugdyzhekova

Результат исследований: Материалы для журналаСтатья

15 Цитирования (Scopus)

Выдержка

1. The κ1 and κ2 opioid receptor agonists U-62066 (8 mg/kg, i.p.) and (-)-bremazocine (0.7mg/kg, i.v.), respectively, both exhibit anti- arrhythmic properties against adrenaline-induced dysrhythmias in rats. 2. In contrast, (+)-bremazocine has no effect on adrenaline-induced dysrhythmias. 3. The κ1 opioid receptor agonists U-50 488 (110 nmol) and [D-Ala2]- dynorphin A (20 nmol) and the κ2 opioid receptor agonist (-)-bremazocine (30 nmol) exhibit pro-arrhythmic properties following intracerebroventricular administration. 4. Prior administration of the κ opioid receptor antagonist nor-binaltorphimine doses i.c.v. (14 nmol), i.p. (10 mg/kg), completely abolishes the pro-arrhythmic (BNI, i.c.v., 14 nmol) as well as anti- arrhythmic (BNI, 10 mg/kg, i.p.) effects of the κ opioid receptor agonists. 5. Neither hexamethonium (10 mg/kg, i.v.) nor atropine (1 mg/kg, i.v.) have any effect on the anti-arrhythmic actions of the κ1 opioid receptor agonist U-62066 following systemic administration. 6. It is suggested that the anti- arrhythmic effects of U-62066 and (-)-bremazocine are associated with the activation of peripheral κ opioid receptors and do not depend on the activation of κ opioid receptors in the autonomic nervous system.

Язык оригиналаАнглийский
Страницы (с-по)716-723
Число страниц8
ЖурналClinical and Experimental Pharmacology and Physiology
Том26
Номер выпуска9
DOI
СостояниеОпубликовано - 1999

Отпечаток

Opioid Receptors
Anti-Arrhythmia Agents
Epinephrine
Dynorphins
Hexamethonium
Narcotic Antagonists
Autonomic Nervous System
Atropine
bremazocine
spiradoline

ASJC Scopus subject areas

  • Physiology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Цитировать

Participation of central and peripheral κ1 and κ2 opioid receptors in arrhythmogenesis. / Lishmanov, Yury B.; Maslov, Leonid N.; Ugdyzhekova, Dina S.

В: Clinical and Experimental Pharmacology and Physiology, Том 26, № 9, 1999, стр. 716-723.

Результат исследований: Материалы для журналаСтатья

@article{c1db1b7c98ab41b9b425980c80eaa167,
title = "Participation of central and peripheral κ1 and κ2 opioid receptors in arrhythmogenesis",
abstract = "1. The κ1 and κ2 opioid receptor agonists U-62066 (8 mg/kg, i.p.) and (-)-bremazocine (0.7mg/kg, i.v.), respectively, both exhibit anti- arrhythmic properties against adrenaline-induced dysrhythmias in rats. 2. In contrast, (+)-bremazocine has no effect on adrenaline-induced dysrhythmias. 3. The κ1 opioid receptor agonists U-50 488 (110 nmol) and [D-Ala2]- dynorphin A (20 nmol) and the κ2 opioid receptor agonist (-)-bremazocine (30 nmol) exhibit pro-arrhythmic properties following intracerebroventricular administration. 4. Prior administration of the κ opioid receptor antagonist nor-binaltorphimine doses i.c.v. (14 nmol), i.p. (10 mg/kg), completely abolishes the pro-arrhythmic (BNI, i.c.v., 14 nmol) as well as anti- arrhythmic (BNI, 10 mg/kg, i.p.) effects of the κ opioid receptor agonists. 5. Neither hexamethonium (10 mg/kg, i.v.) nor atropine (1 mg/kg, i.v.) have any effect on the anti-arrhythmic actions of the κ1 opioid receptor agonist U-62066 following systemic administration. 6. It is suggested that the anti- arrhythmic effects of U-62066 and (-)-bremazocine are associated with the activation of peripheral κ opioid receptors and do not depend on the activation of κ opioid receptors in the autonomic nervous system.",
keywords = "κ opioid receptors, κ opioid receptors, Dysrhythmias",
author = "Lishmanov, {Yury B.} and Maslov, {Leonid N.} and Ugdyzhekova, {Dina S.}",
year = "1999",
doi = "10.1046/j.1440-1681.1999.03115.x",
language = "English",
volume = "26",
pages = "716--723",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Participation of central and peripheral κ1 and κ2 opioid receptors in arrhythmogenesis

AU - Lishmanov, Yury B.

AU - Maslov, Leonid N.

AU - Ugdyzhekova, Dina S.

PY - 1999

Y1 - 1999

N2 - 1. The κ1 and κ2 opioid receptor agonists U-62066 (8 mg/kg, i.p.) and (-)-bremazocine (0.7mg/kg, i.v.), respectively, both exhibit anti- arrhythmic properties against adrenaline-induced dysrhythmias in rats. 2. In contrast, (+)-bremazocine has no effect on adrenaline-induced dysrhythmias. 3. The κ1 opioid receptor agonists U-50 488 (110 nmol) and [D-Ala2]- dynorphin A (20 nmol) and the κ2 opioid receptor agonist (-)-bremazocine (30 nmol) exhibit pro-arrhythmic properties following intracerebroventricular administration. 4. Prior administration of the κ opioid receptor antagonist nor-binaltorphimine doses i.c.v. (14 nmol), i.p. (10 mg/kg), completely abolishes the pro-arrhythmic (BNI, i.c.v., 14 nmol) as well as anti- arrhythmic (BNI, 10 mg/kg, i.p.) effects of the κ opioid receptor agonists. 5. Neither hexamethonium (10 mg/kg, i.v.) nor atropine (1 mg/kg, i.v.) have any effect on the anti-arrhythmic actions of the κ1 opioid receptor agonist U-62066 following systemic administration. 6. It is suggested that the anti- arrhythmic effects of U-62066 and (-)-bremazocine are associated with the activation of peripheral κ opioid receptors and do not depend on the activation of κ opioid receptors in the autonomic nervous system.

AB - 1. The κ1 and κ2 opioid receptor agonists U-62066 (8 mg/kg, i.p.) and (-)-bremazocine (0.7mg/kg, i.v.), respectively, both exhibit anti- arrhythmic properties against adrenaline-induced dysrhythmias in rats. 2. In contrast, (+)-bremazocine has no effect on adrenaline-induced dysrhythmias. 3. The κ1 opioid receptor agonists U-50 488 (110 nmol) and [D-Ala2]- dynorphin A (20 nmol) and the κ2 opioid receptor agonist (-)-bremazocine (30 nmol) exhibit pro-arrhythmic properties following intracerebroventricular administration. 4. Prior administration of the κ opioid receptor antagonist nor-binaltorphimine doses i.c.v. (14 nmol), i.p. (10 mg/kg), completely abolishes the pro-arrhythmic (BNI, i.c.v., 14 nmol) as well as anti- arrhythmic (BNI, 10 mg/kg, i.p.) effects of the κ opioid receptor agonists. 5. Neither hexamethonium (10 mg/kg, i.v.) nor atropine (1 mg/kg, i.v.) have any effect on the anti-arrhythmic actions of the κ1 opioid receptor agonist U-62066 following systemic administration. 6. It is suggested that the anti- arrhythmic effects of U-62066 and (-)-bremazocine are associated with the activation of peripheral κ opioid receptors and do not depend on the activation of κ opioid receptors in the autonomic nervous system.

KW - κ opioid receptors

KW - κ opioid receptors

KW - Dysrhythmias

UR - http://www.scopus.com/inward/record.url?scp=0032835331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032835331&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1681.1999.03115.x

DO - 10.1046/j.1440-1681.1999.03115.x

M3 - Article

C2 - 10499161

AN - SCOPUS:0032835331

VL - 26

SP - 716

EP - 723

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 9

ER -